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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a common and frequently occurring respiratory
disease. At present, western medicine treatment of COPD mainly focuses on symptomatic treatment. Using Chinese
medicines or integrated Chinese and Western medicines to treat stable COPD has significant efficacy. In this study,
we aimed to observe the effect of Radix Stemonae concentrated decoction on the lung tissue pathology and
inflammatory mediators in COPD rats and explore its possible mechanism.
Methods: SD rats were randomized into blank group, COPD model group and Radix Stemonae group, 10 cases in
each group. Rats were fed for 112 days. Before the rats were sacrificed, lung function of the animals was tested. The
right lower lung was fixed for morphologic observation. The inflammatory mediators in serum were determined
using enzyme-linked immuno sorbent assay.
Results: Body weight of animals in the model group was significantly decreased compared with blank group (P < 0.05).
After gavage therapy with Radix Stemonae, body weight was significantly increased (P < 0.05). Compared with the blank
group, pulmonary functions of rats in the model group were significantly abnormal (P < 0.05), while in Radix Stemonae
group, these indicators turned much better than model group (P < 0.05). As for pathological changes in lungs, airway
inflammation in the model group was aggravated. In the Radix Stemonae group, inflammation and emphysema were
much milder. The concentrations of TNF-α, IL-8 and LTB4 in both model group and Radix Stemonae group were
increased significantly (P < 0.05). But the levels in Radix Stemonae group were decreased significantly than model group
(P < 0.05).
Conclusion: Radix Stemonae concentrated decoction may mitigate and improve airway rebuilding in the lungs of COPD
rats by inhibiting the release of inflammatory mediators.
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Background
Chronic obstructive pulmonary disease (COPD) is a
common and frequently occurring respiratory disease,
which is characterized by persistent airflow limitation
[1]. It is often complicated with exacerbations and
hospitalizations [2], which increased mortality and re-
duced life-expectancy [3]. At present, western medicine
treatment of COPD, especially treatment of the stable
stage, mainly focuses on symptomatic treatment [4], and
drug treatment mostly focuses on improving symptoms
and (or) reducing complications [5]. Using Chinese med-
icines or integrated Chinese and Western medicines to
treat stable COPD has significant efficacy [6], improving
pulmonary function and increasing diaphragm muscular
tension [7]. A large amount of high-quality and high-
level evidence has shown that its efficacy in improving
symptoms, reducing exacerbations, and improving
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exercise capacity and quality of life is better than treat-
ment with Western medicines alone [8–10].
Stemonae Radix is a traditional Chinese medicine (TCM)
used as an antitussive and insecticidal remedy, which is
derived from Stemona tuberosa Lour, S. japonica and and
S. sessilifolia [11]. It has been widely used for the treatment
of respiratory diseases in China for thousands of years.
Earlier studies have shown that Stemonae Radix can release
coughs [12], remove phlegm [13] and has antihelminthic,
antibacterial, antituberculous and antifungal activity
[14, 15]. Alkaloids are the major effective ingredients in
Radix Stemonae, which includes stemoninine, stemoninoa-
mide, bisdehydrostemoninine, neotuberostemonine, neoste-
nine, tuberostemonine and tuberostemonine H. Liao et al.
[16] found in an in vitro experiment on guinea pigs that the
extract of Stemona radix had a relaxation effect on airway
smooth muscle and the relaxation effect is realized by inter-
acting with musearinic receptors and dihydropyridine bind-
ing point. Besides, the pharmacokinetics study of multiple
components absorbed in rat plasma after oral administra-
tion of Stemonae radix showed that croomine and tuberos-
temonine would be potential bioactive components for the
treatment of chronic or acute cough in rat model [17, 18].
In previous study of this study group, Radix Stemonae
lung-nourishing fried paste prepared by our hospital
(Hu Yao Zhi Zi Hu 05050323) was used for interference
with patients with stable COPD [19]. And the results
showed that Radix Stemonae lung-nourishing fried paste
could mitigate the clinical symptoms of COPD patients,
improve their quality of life [19]. What’s more, it is safe
and reliable. However, its mechanism of action in treat-
ing COPD was unknown.
In this study, we established SD rat COPD models by
exposing to cigarette smoke combined with intratracheal
instillation of LPS according to the method of Yiping
Song et al. [20]. Radix Stemonae concentrated decoction
was used for gavage therapy. By observation of the effect
of Radix Stemonae concentrated decoction on the lung
tissue pathology and inflammatory mediators in COPD
rats, we tried to explore its possible mechanism of action.
Methods
Ethics statement
All experiments in this study were approved by Ethic
Committee of Shanghai University of Traditional Chinese
Medicine, Shanghai, China.
Animals
Thirty healthy male SD rats with weight of 200 ± 20 g, 10
weeks old were provided by Shanghai SLAC Laboratory
Animal Co., Ltd (Shanghai, China). Rats were housed in
the animal room of Shuguang Hospital 1 week before the
experiment (Shanghai, China). Room temperature was
maintained at 25 ± 1 °C, gas changes at 10~15 times per
hour, relative humidity at (50 ± 10) %, ammonia concen-
tration less than 14 mg/m3, noise ≤60 db. Sterilized diet
and water were freely accessed.
Reagents and drugs
Lipopolysaccharide (LPS) was purchased from Sigma
(USA). Detection kits of TNF-α, IL-8 and LTB4 were pur-
chased from JRDUN Biotechnology Shanghai Co., Ltd
(Shanghai, China). Radix Stemonae Concentrated
Decoction was obtained from Yueyang Hospital of
Integrated Traditional Chinese and Western Medicine
affiliated to Shanghai University of Traditional Chinese
Medicine (Shanghai, China). Daqianmen cigarette (tar
13 mg/stick, nicotine 1.0 mg/stick, carbon monoxide
14 mg/stick) was purchased from Shanghai Tobacco
Group Co., Ltd (Shanghai, China).
Preparation of Radix Stemonae Concentrated Decoction:
It was prepared by the Department of Pharmacy of
Yueyang Hospital. We boiled the raw material in water
twice, concentrated the filtrate to 2 g/mL, and added 70 %
ethanol for precipitation. After 24 h for standing, ethanol
was removed and an appropriate amount of water was
added to dilute the solution to a concentration of 0.6 g/mL.
The amount needed by rats was calculated as 15 times the
clinical dose for human use according to the “Dose
Conversion Coefficients Table per Kilogram of Body
Weight between Animals and Patients” proposed by Jihan
Huang et al. in China [21] (each 250 g of Radix Stemonae
Lung-nourishing Fried Paste contains Radix Stemonae
crude drug 77.5 g; the clinical dose was 10 g/time, TID).
Instruments and equipment
Microplate reader (Labsystems microplate reader, MK3),
pipette (Pipetman, Gilson P), paraffin slicer (Leica,
RM2235), water bath (Leica, HI1210), drying apparatus
(Leica, HI1220 horizontal drying type), embedding
machine (Changzhou Zhongwei Electronic Instrument
Factory, BMJ-111), image analysis system (OLYMPUS,
BX51), animal lung function detector (provided by the
Department of Respiratory Medicine, Shuguang Hospital
Attached to Shanghai University of Traditional Chinese
Medicine, BioSystem XA SFT3410), electronic scales
(Shanghai Precision and Scientific Instrument Co., Ltd.,
HANGPING FA1004N), optical microscope (OLYMPUS,
BX41TF), tray electronic analytical balance (Shimadzu
Corporation, AY220), electrically heated thermostatic
water bath (Sumsung Laboratory Instrument Co., Ltd.,
DK-SD).
Preparation of animal samples
The rats were randomized into blank group, COPD
model group and Radix Stemonae group by using ran-
dom number method, 10 cases in each group. Magenta
(red) and picric acid (yellow) were used to mark the
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experimental animals. COPD model group was prepared
according to the method of Song Yiping et al. [20]. LPS
was injected into rat trachea at a dose of 200 ug (1 g/L)
in the morning of day 1 and day 14; on days 2–13 and
days 15–112, the rats were put in a self-prepared sealed
organic glass poison-stained case for passive smoking,
30 min each time, twice a day at an interval of 2 h. Radix
Stemonae group: the method was the same as the model
group in the first 4 weeks, and from week 5 to week 16,
apart from exposure to cigarette smoke, Radix Stemonae
Concentrated Decoction was used for gavage every day,
3 times a day, 1 mL each time.
Pulmonary function test
On day 112 of the experiment, we firstly performed
pulmonary function tests in rats in vivo according to the
method of Wang et al. [22]. Briefly, the rats were anesthe-
tized by intraperitoneally injection of 2 % sodium pento-
barbital (40 mg/kg), and fixed with a supine position on
the bench. After cutting off the fur in the middle of the
neck, we created an inverted “T”-shaped incision below
the annular cartilage, and performed tracheal intubation
and fixation. The trachea cannula was connected to a
small animal spirometer to measure the ratio between
forced expiratory volume at the time of 0.2 s and forced
vital capacity (FEV0.2/FVC), expiratory peak flow (PEF),
inspiratory resistance (Ri), dynamic lung compliance
(Cldyn) for evaluation of lung function in rats.
Morphologic observation of lung tissue
We fetched the right lower lung and put it in 4 % formal-
dehyde for fixation. Twenty-four hours later, the lung
performed paraffin-embedding and slicing, conventional
slice production, HE staining and routine pathological
examination. We randomly selected 3 fields of view for
each slice under the light microscope to observe the histo-
logical and morphological changes, including pathological
semi-quantitative grading, judgment of the severity of lung
inflammation and tracheal inflammation, and judgment of
degree of alveolar fusion. Mild degree means that infiltra-
tion of lung tissue and various small bronchi by inflamma-
tory cells contained in the lung accounts for less than 1/3
of the whole slice, and alveolar fusion accounts for less
than 1/3 of the field of view of the entire slice. Moderate
degree means that infiltration of lung tissue and various
small bronchi by inflammatory cells contained in the lung
accounts for less than 2/3 of the whole slice, and alveolar
fusion accounts for less than 2/3 of the field of view of the
entire slice. Severe degree means that infiltration of lung
tissue and various small bronchi by inflammatory cells
contained in the lung accounts for more than 2/3 of the
whole slice, and alveolar fusion accounts for more
than 2/3 of the field of view of the entire slice.
Inflammatory mediators in serum and bronchoalveolar
lavage fluid (BALF)
Before the animals were sacrificed, we sampled 5 mL of
their abdominal aortic blood, centrifuged it at 3000 rpm
for 10 min. The supernatant was sub-packed and stored
at −70 °C. We cut open the chest to expose the trachea
and lungs. After the right main bronchus was ligatured,
the left lung was douched with 2 mL normal saline. And
1.5 mL solution (recovery rate 75 %) should be gathered
each time as required, and filtered through gauze. The
left lung was douched with the same method for 3 times.
In total, 4.5 mL solution was recovered, of which 3.5 mL
were centrifuged at 1500 rpm for 15 min, 4 °C. The
supernatant were collected and stored at −70 °C. The
concentrations of TNF-α, IL-8 and LTB4 in serum and
BALF were determined by using enzyme-linked immuno
sorbent assay according to the kit instructions.
Statistical analysis
Statistical analyses were performed using SPSS11.5 pro-
gram. Data were presented as mean ± SD. One-way
ANOVA was adopted for comparison of multi-group
means in line with normalized distribution and homogen-
eity of variance tests; Mann–Whitney was adopted for
paired comparison of means not in line with normalized
distribution and homogeneity of variance tests. A value
with P < 0.05 indicated statistically significant difference.
Results
Comparison of general conditions
In blank group, the rats had smooth and glossy fur,
bright eyes, stable breathing, normal food and water in-
take, good nutrition, healthy body, full muscles, flexible
movements and swift response. In COPD model group,
the rats became manic and upset in the early stage of ex-
posure to cigarette smoke, and successively experienced
sneezing, cough, shortness of breath and other symp-
toms. And in the late stage, the rats showed dry and yel-
low fur. Breathing was fast and shallow in some rats,
slow and deep in some other rats. All rats had decreased
activities, slow movements, low spirits, and reduced food
and water intake. Some rats had a small amount of
sticky secretions at the mouth and nose. While in Radix
Stemonae group, appearance of the rats in the early
stage of exposure to cigarette smoke was the same as in
the COPD model group. The rats became manic and
upset in the early stage of exposure to cigarette smoke,
and successively experienced sneezing, cough, shortness
of breath and other symptoms. After gavaged with Radix
Stemonae, cough, shortness of breath and other symp-
toms in the rats were gradually mitigated, and mental
state and behavioral activities and food and water intake
were gradually normal, but their fur still remained dry
and yellow.
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Body weight of rats
Body weight of the rats was measured on day 1, in week
4, 8 and 16 respectively. The results prompted that com-
pared with the blank group, after rats were exposed to
cigarette smoke for 4 weeks, body weights in the COPD
model group were decreased significantly (P < 0.05).
Compared with the model group, after gavage therapy
with Radix Stemonae for 4 weeks (i.e. in week 8), body
weights were increased (P < 0.05), as shown in Table 1.
Pulmonary function test
The comparison of lung function in three groups was
presented in Table 2. Compared with the blank group, in
the COPD model group, inspiratory resistance (Ri) was
increased significantly (P < 0.05), lung compliance
(Cldyn) was decreased significantly (P < 0.05). The 0.2 s
forced expiratory volume (FEV0.2)/forced vital capacity
(FVC) and expiratory peak flow (PEF) were decreased
significantly (P < 0.05). Compared with the model group,
in the Radix Stemonae group, airway Ri was decreased
significantly (P < 0.05). Cldyn was increased significantly
(P < 0.05), and FEV0.2/FVC (%) and PEF were increased
significantly (P < 0.05).
Pathological changes in rats
Pathological changes in lungs are shown in Fig. 1.
In blank group, the shape and structure of rat bronchi,
pulmonary alveoli and alveolar septa were all normal
(Fig. 1a). The structure of bronchial mucosal epithelium
was intact. Ciliated columnar epithelium was regularly
arranged and a few goblet cells could be seen. There
were few mucosal and lamina propria cells, and no
microglandular hyperplasia was observed. The size of
pulmonary alveoli was normal, the structure was intact,
and local invasion of a small amount of lymphocyte-
dominated inflammatory cells could be seen. There was
no hyperaemia and edema in alveolar septa, no signifi-
cant thickening of the arterial wall, and no expansion of
the alveolar cavity. In COPD model group, the structure
of rat lung tissues was basically normal (Fig. 1b). Muco-
sal epithelium of tracheal and bronchial showed tumid-
ness, disorder, detachment and decreased. The cilia were
lodged, and increased goblet cells and gland hypertrophy
were observed. Mucous plug and a large number of
inflammatory cells could be seen inside the small bron-
chial lumen and gland catheter. Invasion of peripheral
lymphocytes and plasma cells and smooth muscle hyper-
trophy were seen. Terminal bronchiolar mucosal epithe-
lium was irregularly arranged. Alveolar wall turned
thinner and ruptured, and alveolar turned enlargement.
Besides, enlargement and mutual fusion of multiple
alveolar cavities, and emphysema were observed. In
Radix Stemonae group, the structure of rat lung tissues
was basically normal (Fig. 1c). The symptoms of tracheal
and bronchial mucosal epithelial swelling, disorder and
detachment and the increasement of goblet cells were
milder than those in the model group. Inflammatory
cells could be seen inside the small bronchial lumen and
gland catheter, and invasion of peripheral lymphocytes
and plasma cells was observed, which were alleviated to
different degrees compared with the model group.
Hyperplasia and hypertrophy of smooth muscle was
seen; alveolar wall thinning, alveolar enlargement and
fusion of some alveolar cavities were all milder than
those in the model group.
Inflammatory mediators in serum and BALF
Compared with the blank control group, the concen-
trations of TNF-α, IL-8 and LTB4 in serum and BALF
in the COPD model group and the Radix Stemonae
group were increased significantly (P < 0.05). Com-
pared with the model group, the levels of inflammatory
mediators in serum and BALF in the Radix Stemonae
group were all decreased significantly (P < 0.05), as
shown in Tables 3 and 4.
Discussion
COPD is a common and frequently occurring respiratory
disease. After an epidemiological survey among 20,245
adults in seven regions, patients suffering from COPD
account for 8.2 % of the population over the age of 40
[23]. The prevalence of COPD was high, and showed an
increasing trend year by year, and it was the only common
disease that kept rising [24]. Risk for COPD is related to
an interaction between genetic factors and many different
environmental factors, which could also be influenced by
comorbid disease. Environmental factors include tobacco
smoking [25], infections [26], occupational dusts and
chemicals [27], air pollution [28, 29] and other categories
[30]. Smoking and respiratory infections are important
factors in causing COPD. In this study, the method of
exposure to cigarette smoke and intratracheal instillation
of LPS was adopted to simulate the pathological process
of COPD. In the general conditions, cough, shortness of
breath and other clinical manifestations occurred, as well
as weight loss. In pathological conditions, airway and lung
parenchyma inflammation in the COPD model group was
significantly aggravated compared with the blank group,
Table 1 Comparison of rat weights in three groups
Group the first day in week 4 in week 8 in week 16
Blank 206.70 ± 4.19 267.40 ± 3.89 326.10 ± 5.30# 393.70 ± 3.95#
Model 207.50 ± 2.78 248.63 ± 3.96* 309.38 ± 5.63* 376.75 ± 5.65*
Radix
Stemonae
208.20 ± 2.30 249.80 ± 4.34* 318.80 ± 5.67*# 387.00 ± 7.04*#
After One-way ANOVA, *compared with the blank group, there was significant
difference, P < 0.05; #compared with the model group, there was significant
difference, P < 0.05
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and significant emphysema occurred. Pulmonary function
test results also showed that airway resistance in the
model group was increased significantly, compliance was
decreased significantly, and FEV0.2/FVC and PEF were
decreased significantly, suggesting that the model had
been successfully established.
Abnormal expression of TNF-α, IL-8, LTB4 and other
inflammatory mediators have important effects on the
occurrence and acute aggravation of COPD. Inflamma-
tory mediators can cause lung dysfunction and airway
inflammation, as well as systemic inflammatory response
of the body [31]. Therefore, a lot of studies [32, 33] have
explored new approaches of COPD treatment by observ-
ing changes in the levels of inflammatory mediators.
Among them, TNF-α showing chemotaxis effects on
white blood cells, can trigger the occurrence of inflam-
matory response, and may participate in the formation
of emphysema and damage of epithelial cells [34]. Be-
sides, it promotes inflammatory response, tissue fibrosis,
and angiogenesis in the decomposition of extracellular
proteins [35]. The main function of IL-8 is activating
neutrophils and release of oxygen free radicals and pro-
teases, thereby causing injury of pulmonary alveolar
epithelial and microvascular, and playing an important
role in the occurrence and development of airway in-
flammation in COPD patients [36]. LTB4 can recruit
and activate neutrophils, and further expand local in-
flammatory response. Meanwhile, LTB4 has an effect on
increasing infiltration of inflammatory cells in bronchial
mucosa [37]. After gavage therapy with Radix Stemonae,
pulmonary function indicators such as expiratory peak
flow (PEF), inspiratory resistance (Ri), dynamic lung
compliance (Cldyn) turned much better than that in
COPD model group. And the inflammation and
emphysema were much milder. Inflammatory mediators
(TNF-α, IL-8 and LTB4) were decreased significantly in
Radix Stemonae group. Thus Radix Stemonae concen-
trated decoction may mitigate and improve airway re-
building in the lungs of COPD rats by inhibiting the
release of inflammatory mediators.
Radix Stemonae is the dry root of Radix Stemonae
plants Stemona sessilifolia, Stemona japonica or Ste-
mona tuberosa Lour, with a sweet-bitter state and warm
nature, and having an effect on lung channel [38]. The
amount of Radix Stemonae Concentrated Decoction
needed by rats was calculated as 15 times the clinical
dose for human use according to the “Dose Conversion
Coefficients Table per Kilogram of Body Weight between
Animals and Patients” proposed by Jihan Huang et al. in
China [21]. But it is better to optimize the dosage for
Radix Stemonae Concentrated Decoction in a pilot
study.
Modern research literature reports that Radix
Stemonae mainly contains alkaloids [39], including
bisdehydrostemoninine, neotuberostemonine, stemoni-
nine, stemoninoamide, neostenine, tuberostemonine and
tuberostemonine H, which present therapeutic effects in
lung diseases by combating bacteria, eliminating sputum,
stopping cough and relaxing bronchial smooth muscle
[40]. Radix Stemonae alkaloid extract has a relaxing ef-
fect on histamine-induced guinea pig bronchial smooth
muscle spasm, and the effect is slow and sustained. JF
Liao et al. [16] found in an in vitro experiment on
guinea pigs that the water extract of Stemona sessilifolia
had a spasmolytic effect on guinea pig bronchial smooth
muscle and the spasmolytic effect is realized by interact-
ing with musearinic receptors and dihydropyridine bind-
ing point.
By using ultra-performance liquid-chromatography/
mass spectrometry, pharmacokinetics study of multiple
Table 2 Comparison of tested values of lung function in rats
Group Number FEV0.2/FVC (%) PEF (mL/s) Ri (cmH2O · s/L) Cldyn (mL/cmH2O)
Blank 10 82.41 ± 3.68# 75.10 ± 2.78# 0.32 ± 0.02# 0.54 ± 0.05#
Model 10 64.33 ± 6.66* 55.38 ± 4.15* 0.47 ± 0.04* 0.35 ± 0.03*
Radix Stemonae 10 72.22 ± 1.16*# 66.87 ± 3.42*# 0.38 ± 0.01*# 0.47 ± 0.03*#
*Compared with the blank group, there was significant difference, P < 0.05. #Compared with the model group, there was significant difference, P < 0.05
Fig. 1 Photograph of HE-stained lung tissue under optical microscope (×100). a The shape and structure of rat bronchi in blank group. b The
shape and structure of rat bronchi in COPD model group. c The shape and structure of rat bronchi in Radix Stemonae group
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components absorbed in rat plasma after oral adminis-
tration of Stemonae radix showed that that croomine
and tuberostemonine would be potential efficacy
markers [18]. Stemoninine was identified as the major
absorbed compound after oral administration of
Stemonae radix detected by HPLC, which was effective
for chronic or acute cough [17]. In this study, although
we did not extract the active components from Radix
Stemonae Concentrated Decoction, the efficacy compo-
nents for COPD may be some kinds of alkaloids.
Limitations: Still, there are some limitations in the
study. More groups with different dosage of Radix
Stemonae should be supplemented in the study. Besides,
more investigation should be provided to explore the
potential molecular mechanism on treating CODP by
Radix Stemonae. Thus, in the further study, we will
perform more experiments to optimize the dosage for
Radix Stemonae, to identify the active components and
to explore its molecular mechanism.
Conclusion
In this study, Radix Stemonae concentrated decoction
was used for therapying COPD model rats. The patho-
logical results of lung tissues showed that the manifesta-
tions of swelling, disorder and detachment in rat
tracheal and bronchial mucosal epithelial and the in-
creasing in goblet cells were improved significantly
compared with COPD model group. The number of in-
flammatory cells in the small bronchial lumen and gland
catheter was decreased than the model group. Alveolar
wall thinning, alveolar enlargement and fusion were
mitigated in Radix Stemonae group. The test results of
inflammatory mediators in serum and BALF suggested
that Radix Stemonae concentrated decoction could
significantly decrease the concentrations of inflamma-
tory mediators TNF-α, IL-8 and LTB4. Therefore, we
suggested that Radix Stemonae concentrated decoction
can mitigate and improve airway rebuilding in the lungs
of COPD rats by inhibiting the release of inflammatory
mediators, which further delay the deterioration of lung
function.
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